Mark Corrigan, MD
Dr. Corrigan is a leader in life sciences. Following his academic training in psychiatry and appointment at UNC, Dr. Corrigan spent a decade at Pharmacia rising to positions of increasing responsibility ultimately as Group VP for Clinical Research and Experimental Medicine . He then joined Sepracor, a mid-size spec pharma company in the C suite and leading R&D. Following a successful exit, Dr. Corrigan took his first CEO position at Zalicus leading the company through a merger. Subsequent to that effort Dr. Corrigan co-Founded a rare diseases company, Tremeau Pharmaceuticals and following its acquisition, he assumed the leadership of Correvio Pharma, a publically traded, global commercial stage company. Dr. Corrigan has extensive Board experience in research, clinical and commercial stage companies where he has served as Executive Chairman, Chairman, and on all committees. He has led strategic turnarounds and mergers and is unabashedly driven by a passion to create new medicines and bring them successfully to market. He is known for his collaborative and inclusive work style, bringing together diverse skill sets for the benefit of the enterprises he is involved in.